Gemtuzumab Oz the conjugate represents a novel breakthrough in the treatment of aggressive blood leukemia, particularly acute myeloblastic leukemia (AML). The agent pairs a targeted antibody directed at the receptor https://www.targetmol.com/compound/gemtuzumab